Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Adults With Obesity or Overweight Switching From GLP-1RA
NCT07575399Phase 3Recruiting
- Sponsor
- Amgen
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, sponsored by Amgen. Started May 2026; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07575399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575399.